Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
Stock
ALMS
ALMS News & Events
-
Add to Watchlist
Trade ALMS
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Stock Price Prediction
Technical
Valuation
Financials
Earnings
Should I Buy
News & Events
ALMS News
Envudeucitinib Shows Strong Efficacy in Psoriasis Trials
3d ago
Newsfilter
ALUMIS' ENVUDEUCITINIB SHOWS PROMISING EARLY RESULTS IN SKIN CLEARANCE, QUALITY OF LIFE, AND PSORIASIS SYMPTOMS IN TWO PHASE 3 TRIALS, HIGHLIGHTING ITS POTENTIAL AS A TOP ORAL TREATMENT FOR PLAQUE PSORIASIS
3d ago
moomoo
Alumis Reports 2025 Fiscal Year Financial Results
Mar 19 2026
seekingalpha
Wall Street Analysts Adjust Ratings
Feb 26 2026
Benzinga
Wall Street Analysts Adjust Ratings
Feb 25 2026
Benzinga
Wall Street Analysts Adjust Ratings
Feb 25 2026
Benzinga
BML Capital Management Fully Exits Alumis Stake
Feb 03 2026
Fool
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
Feb 02 2026
Benzinga
Show More News
ALMS Events
03/30 12:10
Alumis Stock Drops 16.1% to $20.81
Alumis is down -16.1%, or -$3.99 to $20.81.
Show More Events
ALMS Monitor News
Alumis' Envudeucitinib Shows Strong Efficacy in Psoriasis Trials
Mar 30 2026
Alumis Inc. reaches 52-week high amid market gains
Jan 28 2026
Alumis Inc. shares surge after positive trial results for Envudeucitinib
Jan 06 2026
ALMS Earnings Analysis
No Data
People Also Watch
